WO2007010291A1 - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number
WO2007010291A1
WO2007010291A1 PCT/GB2006/002762 GB2006002762W WO2007010291A1 WO 2007010291 A1 WO2007010291 A1 WO 2007010291A1 GB 2006002762 W GB2006002762 W GB 2006002762W WO 2007010291 A1 WO2007010291 A1 WO 2007010291A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
peptides
peptide according
molecule
seq
Prior art date
Application number
PCT/GB2006/002762
Other languages
English (en)
Inventor
Douglas Campbell Thomson
Joseph David Santangelo
Original Assignee
Singvax Pte Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singvax Pte Ltd. filed Critical Singvax Pte Ltd.
Publication of WO2007010291A1 publication Critical patent/WO2007010291A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to peptides for use in the treatment of hand, foot and mouth disease, in particular to the preparation of vaccines for use against infection by Enterovirus 71.
  • Enterovirus 71 is the major causative agent of hand, foot and mouth disease (HFMD), resulting in major neurological complications including encephalitis, meningitis, neurogenic pulmonary oedema and polio-like paralysis. The disease results in significant mortality in children and infants.
  • HFMD hand, foot and mouth disease
  • EV71 is a picornavirus of the genus enterovirus.
  • Picornaviruses are small, non-enveloped RNA viruses characterised by an isocahedral capsid, composed of 60 copies each of four structural proteins VP1-4.
  • the viral capsid is known to play a significant role in contributing to the pathogenicity of the enteroviruses.
  • Ranganathan et al, Applied Bioinformatics, 2002; 1(1): 43-53 discloses a method for identifying antigenic sites of EV71 using computer modelling.
  • a consensus structural model for EV71 coat protein was obtained and functional regions from closely related viruses were mapped onto the surface of the predicted structure.
  • the method revealed two putative immunogenic regions, one of which was unique to EV71. No experiments were carried out to determine whether the putative immunogenic regions provided a sufficient immunogenic response to make the epitopes viable vaccine candidates.
  • Singh ef a/, Microbiol. Immunol., 2002; 46(1 1): 801-808 describes the sequencing of two EV71 strains; one fatal and one not fatal.
  • the publication discloses homology levels between the two strains and states that the VP1 BC loop region is known to influence neurovirulence. Interestingly, the publication states that attempts to elucidate neurovirulence factors have so far been unsuccessful.
  • the present invention is based on the surprising identification of a consensus VP1 protein which may be used in viral neutralisation.
  • a peptide of the invention comprises the amino acid sequence identified herein as SEQ ID NO: 1 , or a homologue thereof with at least 60% sequence similarity, or a fragment thereof capable of eliciting an immunogenic reaction.
  • an immunogenic composition comprises a peptide as defined above and a pharmaceutically acceptable excipient, diluent or adjuvant.
  • a vaccine composition comprises one or more of the peptides defined above, and an adjuvant.
  • a peptide defined above may be used in the manufacture of a medicament for the treatment of hand, foot and mouth disease.
  • an antibody is raised against a peptide as defined above.
  • a cell comprises a peptide as defined above.
  • a recombinant vector encodes a peptide comprising two or more of the peptides defined above.
  • an assay for screening potential antiviral molecules comprises the steps of:
  • SEQ ID No. 1 shows the Enterovirus 71 (EV71) VP1 consensus sequence according to the invention.
  • EV71 Enterovirus 71
  • SEQ ID No. 1 shows the Enterovirus 71 (EV71) VP1 consensus sequence according to the invention.
  • EV71 Enterovirus 71
  • These positions of variability are represented by an "Xaa" in the sequence, with the variable amino acids identified in the ⁇ 223> fields of the sequence listing.
  • the peptides that may be useful in the various aspects of the invention include those having greater than 60% similarity or identity with the peptide identified herein as SEQ ID No: 1 , or a fragment thereof of at least 5 amino acids of SEQ ID NO: 1 , preferably at least 10, 15, 20, 25, 30 amino acids. More preferably, the peptides have greater than 70%, 80%, 90% or 95% sequence similarity or identity. Most preferably, the peptides have greater than 98% sequence similarity or identity, e.g. 99% similarity or identity.
  • similarity is known in the art and refers to a comparison between amino acid sequences, and takes into account not only identical amino acid sequences at corresponding positions, but also functionally similar amino acids in corresponding positions. Thus similarity between peptide sequences indicates functional similarity, in addition to sequence similarity. Although peptides within the scope of the invention may not retain the biological activity of the VP1 full length protein, they will function to elicit an immunogenic response.
  • Levels of similarity between amino acid sequences can be calculated using known methods.
  • publicly available computer based methods for determining the similarity include the BLASTP, BLASTN and FASTA (Atschul ef a/, J. Molec. Biol., 1990; 215: 403-410), the BLASTX programme available from NCBI, and the Gap programme from Genetics Computer Group, Madison Wl.
  • the levels of similarity provided herein are calculated using the Gap programme with a gap penalty of 12 and a gap length penalty of 4 for determining the amino acid sequence comparisons.
  • peptide is used herein to refer to peptides and proteins.
  • peptide refers to a chain of two or more amino acid residues linked by the peptide linkage.
  • the peptides of the invention are defined with reference to the amino acid sequence specified herein as SEQ ID NO: 1.
  • the amino acid sequence of SEQ ID NO: 1 indicates that there are several positions where alternative amino acid residues may be present. The alternative residues are indicated.
  • Peptides according to the invention may be prepared by methods known in the art. In particular, knowledge of the gene sequence allows the skilled person to use recombinant techniques to express the gene sequence in a suitable host. Methods for the production and isolation of the peptides using gene expression in a suitable host organism will be apparent to the skilled person.
  • the host is a cell that is isolated in vitro, such as a mammalian (human or non-human) cell-line, insect cell- line, bacterial or yeast cell culture.
  • a recombinant vector containing a polynucleotide encoding the peptide of the current invention is within the scope of the invention.
  • the vector is an "expression vector", examples of which will be apparent to the skilled person.
  • the peptides may be made using synthetic peptide chemistry, as will be appreciated by the skilled person.
  • a peptide of the invention comprises an affinity tag.
  • affinity tag refers to a tag that simplifies purification of the protein of interest by use of an interaction between the affinity tag and its binding partner, in affinity chromatography.
  • the affinity tag is an amino acid sequence that is expressed as a fusion polypeptide with the peptide of the invention.
  • Preferred affinity tags include a histidine tag (for example six to ten histidine residues), for purification on a nickel column, and a glutathione-S- transferase tag for purification on a glutathione column.
  • Active fragments and homologues of the peptides can be identified for use in therapy.
  • the term "active fragment” refers to a fragment of the consensus VP1 sequence that retains the ability to elicit an immunogenic response.
  • the immunogenic response generated by the fragment is similar to the response generated by the full-length VP1 consensus sequence.
  • An antibody that binds to an active fragment will also bind to the full-length sequence (in the region that corresponds to the fragment).
  • antibodies raised in an immunogenic response against an active fragment will bind specifically to the full length VP 1 protein.
  • binding affinity between a peptide of the invention and an antibody is in the micromolar range, for example 50 ⁇ M or less, more preferably 10 ⁇ M or less.
  • Vaccine compositions can be formulated with suitable carriers or adjuvants, e.g. alum, as necessary or desired, to provide effective immunisation against infection.
  • suitable adjuvants include, but are not limited to aluminium salts, squalene mixtures, aquiline mixtures, saponin derivatives, immunostimulating complexes (ISCONs), non-ionic block copolymer surfactants and ⁇ -glucan.
  • a suitable amount of an active component of the invention can be selected, for therapeutic use, as can suitable carriers or excipients and routes of administration. These factors are chosen or determined according to known criteria such as the nature/severity of the condition to be treated, the type of health of the subject etc.
  • the peptides of the invention may also be prepared with suitable protective agents which stabilise the peptides on storage.
  • suitable stabilising agents include carbohydrates, e.g. trehalose, sucrose and mannitol.
  • Such stabilising formulations may be prepared with the peptides of the invention incorporated into an amorphous or crystalline carbohydrate structure, for example by spray drying the peptides of the invention together with a stabilising carbohydrate, as disclosed in WO-A-005/053717.
  • compositions of the invention comprising the peptides may be lyophilised after adding a stabiliser.
  • compositions intended for immunisation may be prepared with one of the peptides of the invention or may comprise a combination of two or more for example 3, 4, 5 or more peptides of the invention. If two or more peptides are to be used, these may be presented individually in the immunogenic composition or may be comprised in a single recombinant fusion peptide. For the avoidance of doubt combinations of each peptide, homologue or active fragment described herein are within the scope of the invention.
  • compositions intended for immunisation will be prepared with one or more peptides of the invention or may comprise a combination of one or more peptides of the invention and one or more additional peptides.
  • the one or more additional peptides are useful in generating an immune response to EV71.
  • a composition that is within the scope of the current invention must include the peptide of the invention, as defined above.
  • fusion peptides are well known in the art and will be apparent to the skilled person.
  • a preferred method involves creating a recombinant DNA molecule, preferably an expression vector, comprising the DNA that encodes the peptides to be included in the fusion.
  • the fusion peptide can be expressed from this vector in a cell, preferably an isolated cell in vitro, such as a bacterial, yeast, insect or mammalian cell, or in a cell-free expression system. If two or more peptides are to be used, these may be presented individually in the immunogenic composition or may be comprised in a single recombinant fusion peptide.
  • multiple copies of the same peptide are included in a fusion peptide, such that the peptide is repeated.
  • two or more different peptides are repeated in a fusion peptide.
  • multiple copies of one peptide can be followed by a multiple copies of a second peptide, or alternatively, two peptides can alternate in the fusion peptide so that the combination of the two peptides is repeated.
  • Other suitable combinations and arrangements will be apparent to the skilled person.
  • a peptide of the invention can be linked or conjugated, covalently or non- covalently, to a different molecule, referred to herein as a "heterologous" molecule.
  • the heterologous molecule is an immunomodulating entity.
  • Suitable immunomodulating entities include, but are not limited to, Tetanus Toxoid and Keyhole Cymphocyte Hemocyanin.
  • the peptide defined by SEQ ID No.1 is included in a composition intended for immunisation.
  • the peptide of SEQ ID No.1 and a further peptide of the invention are included in a composition intended to raise an immunogenic response, eg. for immunisation.
  • immunogenic response eg. for immunisation.
  • the term "immunisation” refers to the standard meaning of the term in the art, i.e. the technique of generating a protective immune response in a subject, to provide the subject with resistance against a specific disease.
  • the subject can be a human or a (non-human) animal, such as a (non-human) mammal. Both passive immunisation and active immunisation are within the scope of the invention.
  • Passive immunisation involves producing, outside of the subject of immunisation, protective antibodies that bind to the peptide of the invention. These antibodies are then administered to the subject to provide the protective effect.
  • the protective antibodies can be produced synthetically or, preferably, by an animal such as a rabbit. Methods of generating antibodies to the epitope of the invention, that are suitable for use in passive immunisation, will be apparent to one skilled in the art.
  • Active immunisation involves administering a peptide of the invention to the subject and allowing the subject's own immune system to produce protective antibodies.
  • antibody refers to an immunoglobulin-based molecule that binds to an antigen.
  • the term antibody encompasses all five classes of immunoglobulins (IgG, IgE, IgA, IgM and IgD).
  • Antibody fragments and variations such as Fab and scFv fragments are within the scope of the invention. The skilled person will realise that when an antibody fragment is intended for use in passive immunisation, the Fc region is preferably present.
  • a monoclonal antibody that binds to a peptide of the invention is within the scope of the invention; the use of the peptide of SEQ ID No. 1 to create monoclonal antibodies that bind to the peptide of SEQ ID No. 1 is also within the scope of the invention.
  • Humanised antibodies are also within the scope of the invention.
  • an antibody within the scope of the invention binds to a peptide of the invention.
  • an antibody binds to a peptide of the invention with a K A (affinity constant) in the micromolar range.
  • the antibody binds to a peptide of the invention specifically, so that it binds only to a peptide of the invention and does not bind to other peptides.
  • the antibody is cross-reactive, i.e. it binds to a peptide of the invention and to a heterologous peptide.
  • the heterologous peptide is an epitope from a different enterovirus, i.e. an enterovirus that is not EV71.
  • a preferred heterologous peptide is an epitope from Coxsackie virus 16 (CA16); a preferred antibody therefore binds to a peptide of the invention and a CA16 epitope.
  • CA16 Coxsackie virus 16
  • an antibody within the scope of the invention is cross-reactive (i.e. binds) to a plurality of enteroviruses.
  • an antibody that binds to a plurality of enteroviruses is useful in immunising against a plurality of enteroviruses, and may be used in diagnostic assays for a plurality of enteroviruses.
  • Antibodies raised against the peptides of the invention are useful in therapy or diagnosis.
  • the antibodies may be used in a diagnostic assay to detect EV71 infection in a patient.
  • Suitable immuno-assays making use of the antibodies of the invention will be apparent to the skilled person, based on conventional techniques such as ELISA.
  • the peptides of the invention have been selected to result in viral neutralisation and to eliminate immuno-dominant non-protective epitopes.
  • the peptides are therefore very effective in eliciting a specific immune response to infection by EV71 and are of therapeutic benefit.
  • the peptides of the invention are preferably capable of raising neutralising antibodies against EV71 infection.
  • neutralising antibody refers to an antibody that reduces or removes the ability of a virus to infect a host. Determining the neutralising effectiveness of the peptides may be carried out using the method disclosed in Gomes et a/., Mem. Inst. Oswaldo Cruz, Rio de Janeiro, 2002; 97(1): 47- 49, the content of which is incorporated herein by reference.
  • the peptides of the present invention may also be used in screening assays to identify molecules which may have an antiviral activity.
  • the assay may be performed by contacting the potential antimicrobial molecule with a peptide of the invention, and determining whether the molecule interacts with the peptide.
  • a peptide of the invention is used to screen for monoclonal antibodies that bind to the peptide. Methods for producing and selecting monoclonal antibodies are standard in the art and will be apparent to the skilled person.
  • Suitable molecules that can be screened for antiviral activity include organic chemicals, peptides or nucleic acids. Affinity between the molecule and the peptide may be detected using conventional techniques. For example, the peptide may be immobilised on a support surface and the molecule brought into contact with the peptide and binding detected. The molecule may be labelled, for example with a radiolabel or fluorophore, to permit detection of the binding reaction. Alternatively, the molecule may be immobilised on a support and the peptide brought into contact with the molecule. Unbound peptide can be washed away and the binding interaction determined either on the basis of a label attached to the peptide, or by contacting the peptide with an antibody that is labelled. This is similar to conventional ELISA reactions. A further alternative is to use the peptide as an inhibitor of a reaction between the molecule and its substrate. Competitive inhibition can therefore be used to determine the strength of the binding reaction.
  • a typical assay to screen for potential antiviral molecule comprises contacting a molecule with a peptide of the invention, followed by detection of the interaction between the molecule and the peptide, and selecting those molecules that bind to the peptide.
  • a potential anti-viral molecule binds to the peptide of the invention specifically, as discussed above with reference to antibody binding, with an affinity constant in the micromolar range, for example 50 ⁇ M or less, preferably 10 ⁇ M or less.
  • the molecules that bind in this way are potentially anti-viral, and any anti-viral properties can be investigated further.
  • a molecule that is identified by a screening assay as detailed herein is therefore a potential anti-viral molecule.
  • the peptides of the invention are of general benefit in the treatment or prevention of hand, foot and mouth disease, in both humans and (non-human) animals. While intended primarily as a therapy against infection by EV71 , the peptides may also be of use in treating or preventing infection by Coxsackie virus 16 (CA16).
  • CA16 Coxsackie virus 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un peptide qui comprend la séquence d’acides aminés identifiée ici comme SEQ ID NO: 1 ou un homologue de celle-ci avec au moins 60% de similarité de séquence, ou un fragment de celle-ci capable de provoquer une réaction immunogénique. Les peptides de l'invention sont utiles dans le traitement du syndrome pieds-mains-bouche.
PCT/GB2006/002762 2005-07-22 2006-07-24 Vaccin WO2007010291A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0515135.2 2005-07-22
GBGB0515135.2A GB0515135D0 (en) 2005-07-22 2005-07-22 Vaccine

Publications (1)

Publication Number Publication Date
WO2007010291A1 true WO2007010291A1 (fr) 2007-01-25

Family

ID=34976441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002762 WO2007010291A1 (fr) 2005-07-22 2006-07-24 Vaccin

Country Status (2)

Country Link
GB (1) GB0515135D0 (fr)
WO (1) WO2007010291A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148149A1 (fr) * 2007-06-05 2008-12-11 Anadis Ltd Procédé de traitement ou d'inhibition des infections à entérovirus 71
CN101851631A (zh) * 2010-03-16 2010-10-06 徐娟 一种密码子优化的ev71 vp1基因及其核酸疫苗
US20110179508A1 (en) * 2008-11-19 2011-07-21 National Chung Hsing University Enterovirus type 71 protein and method for production
WO2013032404A1 (fr) * 2011-08-26 2013-03-07 Temasek Life Sciences Laboratory Limited Anticorps anti-entérovirus humain spécifique et ses applications dans les diagnostics
CN108663523A (zh) * 2017-03-31 2018-10-16 复旦大学 可用于诊断人肠道病毒71型感染的试剂盒

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BROWN BETTY A ET AL: "Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998", JOURNAL OF VIROLOGY, vol. 73, no. 12, December 1999 (1999-12-01), pages 9969 - 9975, XP002403702, ISSN: 0022-538X *
CHEN ET AL: "Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 15, 5 April 2006 (2006-04-05), pages 2944 - 2951, XP005337661, ISSN: 0264-410X *
CHIU ET AL: "Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71", MICROBES AND INFECTION, ELSEVIER, PARIS, FR, vol. 8, no. 7, 21 April 2006 (2006-04-21), pages 1671 - 1678, XP005586874, ISSN: 1286-4579 *
LIN Y-C ET AL: "Characterization of a vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 19-20, 7 June 2002 (2002-06-07), pages 2485 - 2493, XP004359678, ISSN: 0264-410X *
RANGANATHAN SHOBA ET AL: "The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling.", APPLIED BIOINFORMATICS. 2002, vol. 1, no. 1, 2002, pages 43 - 52, XP001247569, ISSN: 1175-5636 *
SHEU J J C ET AL: "PREPARATION OF RECOMBINANT HUMAN ANTI-ENTEROVIRUS 71 NEUTRALIZING ANTIBODIES FOR CLINICAL APPLICATIONS", FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. ANNUAL MEETING. ABSTRACTS OF PAPERS, XX, XX, vol. 16, no. 4, 24 April 2002 (2002-04-24), pages A308, XP009052166 *
SHIH SHIN-RU ET AL: "Expression of caspid protein VP1 for use as antigen for the diagnosis of enterovirus 71 infection", JOURNAL OF MEDICAL VIROLOGY, vol. 61, no. 2, June 2000 (2000-06-01), pages 228 - 234, XP002403704, ISSN: 0146-6615 *
SHIH SHIN-RU ET AL: "Genetic analysis of enterovirus 71 isolated from fatal and non-fatal cases of hand, foot and mouth disease during an epidemic in Taiwan, 1998", VIRUS RESEARCH, vol. 68, no. 2, July 2000 (2000-07-01), pages 127 - 136, XP002403703, ISSN: 0168-1702 *
SIVASAMUGHAM LALITA AMBIGAI ET AL: "Recombinant Newcastle disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits", JOURNAL OF MEDICAL VIROLOGY, vol. 78, no. 8, 20 June 2006 (2006-06-20), pages 1096 - 1104, XP002403705, ISSN: 0146-6615 *
WU C-N ET AL: "Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 5-6, 12 December 2001 (2001-12-12), pages 895 - 904, XP004312535, ISSN: 0264-410X *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148149A1 (fr) * 2007-06-05 2008-12-11 Anadis Ltd Procédé de traitement ou d'inhibition des infections à entérovirus 71
US20110179508A1 (en) * 2008-11-19 2011-07-21 National Chung Hsing University Enterovirus type 71 protein and method for production
US8168192B2 (en) * 2008-11-19 2012-05-01 National Chung Hsing University Enterovirus type 71 protein and method for production
US8313750B2 (en) * 2008-11-19 2012-11-20 National Chung Hsing University Enterovirus type 71 protein and method for production
CN101851631A (zh) * 2010-03-16 2010-10-06 徐娟 一种密码子优化的ev71 vp1基因及其核酸疫苗
CN101851631B (zh) * 2010-03-16 2013-04-17 徐娟 一种密码子优化的ev71 vp1基因及其核酸疫苗
WO2013032404A1 (fr) * 2011-08-26 2013-03-07 Temasek Life Sciences Laboratory Limited Anticorps anti-entérovirus humain spécifique et ses applications dans les diagnostics
CN103841993A (zh) * 2011-08-26 2014-06-04 淡马锡生命科学实验室有限公司 人肠道病毒特异性抗体及其在诊断中的应用
CN108663523A (zh) * 2017-03-31 2018-10-16 复旦大学 可用于诊断人肠道病毒71型感染的试剂盒

Also Published As

Publication number Publication date
GB0515135D0 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
Foo et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides
Hermida et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates
AU776844B2 (en) Early detection of flaviviruses using the NS1 glycoprotein
JP2009524581A (ja) デング熱ウイルスの４種の血清型及び他のフラビウイルス属の予防的処置及び／又は治療的処置のための方法及びタンパク質
US10016496B2 (en) Respiratory syncytial virus F protein epitopes
KR102673090B1 (ko) 합성 폴리펩타이드 에피토프 기반의 백신 조성물
US12064476B2 (en) Zika virus immunogenic compositions
JP7382634B2 (ja) 交差免疫抗原ワクチン及びその調製方法
Zhang et al. Antigenic characteristics of the complete and truncated capsid protein VP1 of enterovirus 71
WO2017165317A2 (fr) Thérapies, vaccins et procédés prédictifs pour flavivirus
Li et al. Recombinant subunit ORF2. 1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein
US20130071418A1 (en) Physicochemical (PCP) Based Consensus Sequences and Uses Thereof
Ershova et al. Recombinant domains III of Tick-Borne Encephalitis Virus envelope protein in combination with dextran and CpGs induce immune response and partial protectiveness against TBE virus infection in mice
JP2007537137A (ja) ノロウィルスモノクローナル抗体及びペプチド
Deng et al. Immunogenicity of recombinant human bocavirus‐1, 2 VP 2 gene virus‐like particles in mice
WO2007010291A1 (fr) Vaccin
Li et al. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals
Yang et al. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli
CN105085672B (zh) 3d蛋白特异性单克隆免疫球蛋白a抗体及其组合物
US7279164B2 (en) Chimeric proteins that induce effects directed against viruses
CN105085671B (zh) 抗肠道病毒3d蛋白的单克隆免疫球蛋白g抗体及其免疫原性组合物
Zhang et al. Efficient capture and detection of Zika virion by polyclonal antibody against prokaryotic recombinant envelope protein
Li et al. Identification of a conserved linear epitope using a monoclonal antibody against non-structural protein 3B of foot-and-mouth disease virus
JP7145863B2 (ja) 改変型ＨＳＶ ｇＢタンパク質及びこれを含むＨＳＶワクチン
US20090162369A1 (en) Synthetic chimeric peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06765089

Country of ref document: EP

Kind code of ref document: A1